Korea vs United States of America: Share of adolescent girls vaccinated against human papillomavirus
Korea
65.0%
in 2024
United States of America
65.0%
in 2024
Korea rank
38th
United States of America rank
38th
Share of adolescent girls vaccinated against human papillomavirus over time
- Korea
- United States of America
How they compare
Korea currently reports 65.0% against 65.0% in United States of America, a difference of 0.0%.
The two have swapped places 4 times across 7 shared years of data; in 2018 it was United States of America ahead.
Korea ranks 38th and United States of America ranks 38th of 74 countries.
Across the 2 decades both report, Korea averaged higher in 1 and United States of America in 1.
Head to head by decade
| Decade | Korea | United States of America | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 55.5% | 58.5% | 3.0% | United States of America |
| 2020s | 69.4% | 66.2% | 3.2% | Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of adolescent girls vaccinated against human papillomavirus, Korea or United States of America?
- Korea, at 65.0% against 65.0% in United States of America as of 2024.
- What is the difference in share of adolescent girls vaccinated against human papillomavirus between Korea and United States of America?
- 0.0%, with Korea ahead.
- How many years of comparable data are there for Korea and United States of America?
- 7 years are reported by both, from 2018 to 2024.
- How do Korea and United States of America rank globally for share of adolescent girls vaccinated against human papillomavirus?
- Korea ranks 38th and United States of America ranks 38th of 74 countries.
- Where does this data come from?
- WHO & UNICEF (2025) – processed by Our World in Data, published as Share of adolescent girls vaccinated against human papillomavirus. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of fifteen-year-old girls who, between the ages of 9 and 14, received their last dose of the human papillomavirus vaccine.